Short answer
Aura Biosciences, Inc. (AURA) filed an 8-K current report with the SEC on August 11, 2026 reporting Item 2.02 (Results of Operations and Financial Condition), Item 2.05 (Costs Associated with Exit or Disposal Activities), Item 5.02 (Departure/Election of Directors or Officers), Item 8.01 (Other Events), Item EX-99.1 (Exhibit EX-99.1). Q2 2026 results covered quarter ended June 30, 2026.
Aura Biosciences, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 2.02 · Results of Operations and Financial Condition
- Q2 2026 results covered quarter ended June 30, 2026
- Press release issued August 11, 2026
- Full financial details furnished in Exhibit 99.1 for investor review
Item 2.05 · Costs Associated with Exit or Disposal Activities
- Workforce reduction of approximately 20% as Aura refocuses resources on ocular oncology
- NMIBC program resource allocation to be minimized, signaling reduced strategic emphasis on bladder cancer
- Estimated Realignment costs of $2.9M–$3.2M, with significant majority expected in Q3 2026
- Severance payments contingent on employee execution and non-revocation of release agreements
- Additional restructuring costs remain possible beyond current estimates
Item 5.02 · Departure/Election of Directors or Officers
- Susan Abu-Absi appointed COO effective August 10, 2026, adding an operational leader with prior biotech manufacturing and development experience
- COO compensation includes $520,000 base salary, 45% target annual bonus, and approximately 400,000 inducement shares
- CFO and Business Officer Anthony Gibney departs September 1, 2026, with nine months’ salary continuation and consulting through May 31, 2027
- Amy Elazzouzi becomes interim principal financial officer September 2, 2026, leveraging her tenure with Aura since 2015
- CFO transition creates near-term finance leadership uncertainty while Gibney’s consulting arrangement supports continuity through May 31, 2027
Item 8.01 · Other Events
- Broad forward-looking disclaimer covering clinical, regulatory, financing, and trial-execution risks
- Phase 3 Special Protocol agreement with FDA remains subject to potential regulatory disagreement
- Clinical results, including interim data, may not predict final outcomes or future trial performance
- Cash resources may be insufficient for foreseeable and unforeseeable operating and capital requirements
Item EX-99.1 · Exhibit EX-99.1
- Phase 3 CoMpass fully enrolled with 108 patients; topline data remain targeted for 2H 2027 under an FDA SPA
- Ocular oncology becomes the core strategy; NMIBC investment reduced despite 81% three-month response and 69% complete response rates
- Cash, equivalents and marketable securities totaled $323.8M, supporting projected operations into 1H 2029
- Quarterly net loss widened to $45.6M from $27.0M; R&D rose to $30.7M and G&A to $17.3M
- Approximately 20% workforce reduction and $2.9M-$3.2M restructuring charges accompany leadership turnover and cost realignment
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Aura Biosciences, Inc. 8-K filings
Get the next AURA 8-K as it lands
Follow AURA for push alerts, or ask the research agent what this filing means.